Codexis discovers, develops, and sells enzymes and proteins through two segments: Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services, including screening and protein engineering. The company also has a technology platform called CodeEvolver for developing biocatalysts. Codexis collaborates with Nestlé Health Science on CDX-7108 for exocrine pancreatic insufficiency treatment. Products are sold to pharmaceutical manufacturers through direct sales in the US and Europe.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |